Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

Novo CEO says setbacks demand faster research, acquisitions as investors fret over pipeline

Novo Nordisk CEO Mike Doustdar said the company will speed up research and pursue smaller acquisitions to strengthen its drug pipeline after recent trial setbacks. The company raised its 2026 sales and profit outlook, but shares fell as investors focused on weaker-than-expected Wegovy pill sales and another setback for obesity…

The Economic Times

Novo Nordisk Stock Slides After Outlook Disappoints. But Wegovy Sales Continue to Climb

U.S.-listed shares of Novo Nordisk fell more than 6% after the company raised its full-year 2026 outlook but signaled that sales and profit could still decline compared with the previous year.

International Business Times

A Next-Generation Obesity Drug Has Been Released By Eli Lilly in Early Access to Select Patients

Eli Lilly will offer early access to the investigational obesity drug retatrutide after positive Phase 3 trials showed significant weight-loss results.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Drugmaker Pfizer beats earnings estimates, targets $2.5 billion in additional cost cuts

Pfizer has reported impressive second-quarter earnings, driven by the success of Eliquis and newly acquired pharmaceutical products. The company is planning $2.5 billion in cost-saving measures expected to be in place by 2029. With a focus on innovative treatments, Pfizer aims to reduce reliance on older, high-grossing medications and looks…

The Economic Times

Analysis of 19 Trials Finds GLP-1 Results Differ by Drug and Dose, Pointing Toward More Tailored Obesity Care

A 19-trial analysis found GLP-1 drugs and doses differ across seven heart and metabolic measures. It does not yet tell doctors which one to pick.

Medical Daily

New Study Links Daily Avocado to Lower Heart Disease Risk and Here's What It Means for Your Heart

A new study suggests eating one avocado daily may improve cholesterol markers linked to heart disease when included in an overall heart-healthy diet.

Medical Daily

What Is Retatrutide? The Next-Gen GLP-1 Poised to Become the Most In-Demand Peptide

A deep dive into Retatrutide shows promise—and a lot of danger.

Marie Claire

Read news from The Economist, FT, and more,
with one subscription

Ultra-processed food companies hindering health drives by suing countries, says WHO

Exclusive: Director general accuses corporations of obstructing efforts to tackle obesity crisis after investigation by Guardian and others

The Guardian - UK

Alcohol’s hidden calories: product labels could help fight obesity in South Africa

South Africa is grappling with an obesity crisis. Nearly half of adults are overweight or obese. Public discussion often focuses on ultra-processed foods and sugary drinks as reasons for weight gain. But there’s another source of calories that’s often overlooked: alcoholic drinks.

The Conversation

GLP-1 Drugs Did Not Lower Relapse Risk in Crohn's and Colitis Patients, a Large Claims Analysis Found

A claims study found GLP-1 drugs did not reduce IBD relapse in patients with obesity or diabetes, and did not raise safety events.

Medical Daily

GLP-1 Medicare Coverage: How to Get It for $50 (And the Catch)

A new CMS program finally brings Wegovy and Zepbound within reach for seniors. But a hidden rule about your deductible could cost you thousands.

Kiplinger

Denied Coverage For Wegovy Or Zepbound? Here Is What The Latest Value Assessment Says About Price And Access

Denied for Wegovy or Zepbound? A new value analysis explains why plans refuse coverage and what exceptions and appeals actually involve.

Medical Daily

ICER Finds Weight-Loss Drugs Cost-Effective, But Analysts Warn the Projected Savings Depend on Patients Staying On Them

ICER finds GLP-1s cost-effective for obesity, but analysts warn projected savings assume patients stay on treatment. What it means for coverage.

Medical Daily

Millions of people are losing weight using GLP-1s. How do the drugs affect their love lives?

Prescribing doctors often warn of the medications’ potential side-effects – but unexpected impacts on romantic relationships are less understood

The Guardian - AU

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

Novo Nordisk pursues preliminary injunction to block Eli Lilly weight-loss drug ads

Novo Nordisk is seeking a court injunction to stop Eli Lilly's drug advertisements. The Danish company claims Lilly's ads mislead consumers about treatment comparisons. Lilly denies wrongdoing and stands by its advertising claims. Both companies compete in the growing obesity and diabetes drug market. Novo Nordisk argues Lilly uses outdated…

The Economic Times

Make junk food costlier, tighten school canteen rules: Five steps ICMR suggests to curb childhood obesity

India faces a significant childhood obesity crisis with 41 million affected children. New government policies aim to curb unhealthy food marketing and improve school food options. Easy-to-understand food labels will help parents make informed choices for their families. Dedicated health taxes on unhealthy foods and beverages are also proposed. These…

International Business Times

Eli Lilly Cleared Two More Trials For Its Next-Generation Obesity Drug. It Will Seek FDA Approval Next Year

After 80 weeks of treatment, obese, non-diabetic participants receiving retatrutide lost an average of 22.6% of their body weight while also showing improvements in several cardiometabolic risk factors.

Medical Daily

Heart Attack Deaths Have Fallen Dramatically Over 33 Years: A New Study Pinpoints Exactly What Worked

A JAMA Cardiology 33-year analysis found modifiable risk factors drove a dramatic decline in U.S. heart attack deaths. But BMI and blood sugar-related deaths are increasing.

Get all your
news in one place.

100's of premium titles.
One news app.

Medical Daily

Medicare's New GLP-1 Weight Loss Drug Program Launched July 1, but It Expires in 2027 with No Successor in Place

The Medicare GLP-1 Bridge launched July 1, 2026 at $50/month for eligible beneficiaries. It expires December 31, 2027, with the permanent BALANCE replacement indefinitely delayed.

Medical Daily

The First Oral GLP-1 Weight Loss Pill With No Food or Injection Requirements Is Now Available

Eli Lilly's Foundayo (orforglipron) is the first oral GLP-1 obesity pill with no food or water restrictions. FDA approved it April 1, 2026. Here is what patients should know.

Fortune

The GLP-1 paradox: too expensive to cover, too effective to cut

A founder and a former HHS CTO agree: GLPs are breaking the healthcare system. We need to move away from drug-first or diet-first obesity care.

Bangkok Post

Gold card health scheme to cover obesity surgery

The National Health Security Office (NHSO) has expanded benefits under the Universal Coverage Scheme, commonly known as the 30-baht gold card scheme, to include surgery for patients with severe obesity who meet strict medical criteria.

International Business Times UK

Type 2 Diabetes Jumped 69% in Young Women, Nearly 60% Higher Than in Men, as Obesity Starts Earlier

A study reveals a 69% rise in type 2 diabetes among young women in England since 2011, highlighting early obesity as a key factor. The NHS is responding with targeted initiatives.

The Guardian - UK

Target ultra-processed food to reduce obesity in Britain

Letter: James Capon responds to an editorial on the health select committee’s call for radical action to regulate food markets

Medical Daily

GLP-1 Drugs Like Ozempic Carry Elevated Risks of Muscle Loss and Malnutrition in Adults Over 65

GLP-1 drugs carry higher muscle loss, malnutrition, and bone density risks in adults over 65 that younger users don't face. Here's what older patients and prescribers need to know.

1 2 3 4 5

People

Tedros Adhanom Ghebreyesus

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Imperial College London

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.